Companies Nurix Therapeutics, Inc.

Nurix Therapeutics (NRIX): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Nurix Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$6,374,138CEO Arthur Sands · source

Say-on-pay support91.31%Latest vote · source

CEO vs. named peers76th pct.Of 21 peer CEOs

CEO pay ratio23:1To the median employee · source

CEO pay, last three years

$4,363,120FY2023
$5,812,862FY2024
$6,374,138FY2025

CEO total pay was $6,374,138 in fiscal 2025, up from $5,812,862 in fiscal 2024.

FY2025: salary $674,584 · bonus $0 · stock awards $0 · option awards $5,166,196

Executives and directors

Arthur Sands · CEO Christine Ring · General Counsel Gwenn Hansen · Chief Scientific Officer Hans van Houte · CFO Anil Kapur · Independent Director David L. Lacey · Independent Director Edward C. Saltzman · Independent Director Judith A. Reinsdorf · Independent Director Julia P. Gregory · Independent Director Lori A. Kunkel · Former director (through FY2025)Paul M. Silva · Independent Director Roger Dansey · Independent Director Roy D. Baynes · Independent Director

Frequently asked questions

Who was the highest-paid executive at Nurix Therapeutics, Inc. in fiscal 2025?

As disclosed, Arthur Sands (President, Chief Executive Officer and Director) was the highest-paid executive at Nurix Therapeutics, Inc. in fiscal 2025, with total compensation of $6,374,138.

How does Nurix Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?

As disclosed, Arthur Sands's total compensation ranked at the 76th percentile of Nurix Therapeutics, Inc.'s disclosed peer group.

What is Nurix Therapeutics, Inc.'s CEO-to-median employee pay ratio?

As disclosed, Nurix Therapeutics, Inc.'s CEO-to-median employee pay ratio was 23:1.

How did shareholders vote on Nurix Therapeutics, Inc.'s executive compensation?

As disclosed, 91.31% of shareholders supported Nurix Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.

How much does Nurix Therapeutics, Inc. spend in total on board compensation for fiscal 2025?

As disclosed, Nurix Therapeutics, Inc. reported total board compensation of $538,233 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Arthur Sands	$674,584	$0	$0	$5,166,196	$510,000	$0	$23,358	$6,374,138
President, Chief Executive Officer and Director
Gwenn Hansen	556,000	0	770,816	861,033	307,440	0	2,835	2,498,124
Chief Scientific Officer
Hans van Houte	545,833	0	587,216	861,033	298,238	0	4,183	2,296,503
Chief Financial Officer
Christine Ring	527,500	0	587,216	861,033	283,815	0	3,773	2,263,337
Chief Legal Officer and Chief Compliance Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Arthur Sands	$6,374,138	$5,812,862	$4,363,120	↑ +561,276
Gwenn Hansen	2,498,124	2,033,860	1,632,757	↑ +464,264
Hans van Houte	2,296,503	2,016,482	1,611,987	↑ +280,021
Christine Ring	2,263,337	2,016,484	—	↑ +246,853

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The compensation program is designed to align executive interests with the drivers of growth and stockholder returns by supporting the achievement of primary business goals. It embraces a performance-oriented philosophy focused on rewarding executives for the creation of long-term value, with a heavy weighting toward variable, at-risk pay through short-term cash incentives and long-term equity awards.

CEO STI target (% of salary)	60%
CEO LTI target (% of salary)	—
Independent consultant	Aon plc
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Gwenn Hansen	OPTION	2025-02-11	—	—	75,000	—	$861,033
Arthur Sands	OPTION	2025-02-11	—	—	450,000	—	5,166,196
Gwenn Hansen	RSU	2025-02-11	—	—	34,300	—	587,216
Gwenn Hansen	RSU	2025-10-14	—	—	20,000	—	183,600
Christine Ring	RSU	2025-02-11	—	—	34,300	—	587,216
Hans van Houte	RSU	2025-02-11	—	—	34,300	—	587,216
Christine Ring	OPTION	2025-02-11	—	—	75,000	—	861,033
Hans van Houte	OPTION	2025-02-11	—	—	75,000	—	861,033

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Gwenn Hansen	$770,816	$0	$861,033	0.0%
Arthur Sands	0	0	5,166,196	0.0%
Christine Ring	587,216	0	861,033	0.0%
Hans van Houte	587,216	0	861,033	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Christine Ring	RSU	1,925	—	$34,034
Christine Ring	Option	2,886	19.49	—
Hans van Houte	RSU	2,887	—	51,042
Gwenn Hansen	RSU	3,207	—	56,700
Hans van Houte	RSU	4,000	—	70,720
Gwenn Hansen	RSU	4,000	—	70,720
Christine Ring	RSU	4,000	—	70,720
Hans van Houte	Option	4,329	19.49	—
Gwenn Hansen	Option	4,810	19.49	—
Hans van Houte	Option	7,409	10.83	—
Gwenn Hansen	Option	7,409	10.83	—
Christine Ring	Option	7,409	10.83	—
Christine Ring	Option	7,537	18.5	—
Gwenn Hansen	Option	11,306	18.5	—
Arthur Sands	Option	12,500	18.89	—
Gwenn Hansen	RSU	20,000	—	353,600
Hans van Houte	RSU	22,500	—	397,800
Gwenn Hansen	RSU	22,500	—	397,800
Christine Ring	RSU	22,500	—	397,800
Hans van Houte	Option	22,500	18.5	—
Hans van Houte	RSU	28,584	—	505,365
Gwenn Hansen	RSU	28,584	—	505,365
Christine Ring	RSU	28,584	—	505,365
Arthur Sands	Option	37,334	10.83	—
Hans van Houte	Option	56,250	17.12	—
Gwenn Hansen	Option	56,250	17.12	—
Christine Ring	Option	56,250	17.12	—
Hans van Houte	Option	62,500	8.72	—
Gwenn Hansen	Option	62,500	8.72	—
Christine Ring	Option	62,500	8.72	—
Arthur Sands	Option	75,000	18.5	—
Arthur Sands	Option	333,334	8.72	—
Arthur Sands	Option	337,500	17.12	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Roy D. BaynesIndependent · Clinical and Commercialization (Chair) · Partial-year service	$44,479	$0	$624,307	—	$0	$668,786
Roger DanseyIndependent · Clinical and Commercialization · Partial-year service	4,792	0	416,892	—	0	421,684
Julia P. GregoryIndependent · Audit · Nominating and Corporate Governance	101,458	0	157,509	—	1	258,968
Paul M. SilvaIndependent · Audit (Chair) · Compensation	72,813	0	157,509	—	0	230,322
Judith A. ReinsdorfIndependent · Audit · Nominating and Corporate Governance (Chair) · Partial-year service	71,563	0	157,509	—	0	229,072
David L. LaceyIndependent · Clinical and Commercialization · Compensation (Chair) · Partial-year service	69,063	0	157,509	—	0	226,571
Edward C. SaltzmanIndependent · Clinical and Commercialization · Compensation	62,708	0	157,509	—	1	220,218
Anil KapurIndependent · Nominating and Corporate Governance · Clinical and Commercialization	60,417	0	157,509	—	0	217,926
Lori A. KunkelIndependent · Departed during FY · Partial-year service	50,938	0	157,509	—	0	208,447

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$157,509
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 15,000 / 15,000
Stock ownership guideline	—

Total cost of the board

Component	FY2025
Cash retainers and fees	$538,231
Equity awards (grant-date value)	$0
All other compensation	$2
Total cost of the board	$538,233

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Nurix Therapeutics as a peer

Companies that benchmark against NRIX

7 companies name NRIX as a compensation peer

The list of companies that name NRIX as a peer is temporarily unavailable — recheck shortly.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies Nurix Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.

C4 Therapeutics, Inc. (CCCC)¹⁷⁷Sutro Biopharma Inc. (STRO)¹⁷⁸

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Arcellx Inc.	2024	Rami Elghandour	$653,288	$9,342,069	$10,850,151	$0	$21,402,668
2	Arcus Biosciences, Inc.	2025	Terry Rosen	775,000	2,199,450	6,008,860	658,750	9,656,813
3	Ideaya Biosciences, Inc.	2025	Yujiro Hata	700,000	0	8,418,840	378,000	9,512,640
4	Kymera Therapeutics Inc.	2025	Nello Mainolfi	693,000	0	7,318,859	519,750	8,545,609
5	Arvinas, Inc.	2025	John Houston	706,236	2,685,840	2,671,051	457,000	6,534,127
6	Nurix Therapeutics, Inc.	2025	Arthur Sands	674,584	0	5,166,196	510,000	6,374,138
7	Iteos Therapeutics Inc.	2024	Michel Detheux	628,684	0	4,965,264	421,014	6,085,657
8	Replimune Group Inc.	2026	Sushil Patel	700,000	3,376,003	1,448,325	315,000	5,845,982
9	Oric Pharmaceuticals Inc.	2025	Jacob Chacko	657,500	826,000	3,634,560	434,000	5,567,164
10	Celldex Therapeutics, Inc.	2025	Anthony Marucci	785,804	0	4,027,590	0	5,366,709
11	Recursion Pharmaceuticals Inc.	2025	Najat Khan	600,000	1,944,547	2,501,058	256,777	5,349,065
12	Cullinan Therapeutics, Inc.	2025	Nadim Ahmed	698,476	1,697,400	2,234,340	419,086	5,100,006
13	Intellia Therapeutics Inc.	2025	John Leonard	708,000	2,443,920	1,356,320	0	5,063,899
14	Monte Rosa Therapeutics Inc.	2025	Markus Warmuth	650,000	910,080	3,043,648	429,000	5,032,728
15	Kura Oncology Inc.	2025	Troy Wilson	700,000	0	3,297,250	630,000	4,735,016
16	Relay Therapeutics Inc.	2025	Sanjiv Patel	707,846	0	3,513,900	424,708	4,646,454
17	Erasca, Inc.	2025	Jonathan Lim	670,400	0	3,135,250	482,688	4,298,838
18	IGM Biosciences Inc.	2023	Fred Schwarzer	646,797	868,050	1,336,743	355,738	3,207,328
19	C4 Therapeutics, Inc.	2025	Andrew Hirsch	694,925	710,730	848,007	573,313	2,940,975
20	Tango Therapeutics Inc.	2025	Barbara Weber	697,950	308,096	1,275,328	524,250	2,823,992
21	Sutro Biopharma Inc.	2025	William Newell	239,693	0	0	0	1,671,311
22	Zentalis Pharmaceuticals Inc.	2025	Julie Eastland	700,000	99,772	56,975	441,000	1,300,731

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Nurix Therapeutics, Inc.	not disclosed	Option 60 · RSU 40	not disclosed	Aon plc
Arcellx Inc.	140%	not disclosed	No	Meridian Compensation Partners
Arcus Biosciences, Inc.	100%	Options 67 · RSU 33	not disclosed	Radford
Arvinas, Inc.	108%	Options 50 · RSU 50	not disclosed	Aon (Aon's Human Capital Solutions practice, a division of Aon plc)
C4 Therapeutics, Inc.	120%	not disclosed	not disclosed	Pearl Meyer
Celldex Therapeutics, Inc.	100%	Options 100	not disclosed	Aon (Human Capital Solutions practice, a division of Aon plc)
Cullinan Therapeutics, Inc.	not disclosed	not disclosed	not disclosed	Compensia (through June 2025); Pay Governance (since June 2025)
Erasca, Inc.	120%	Options 100	not disclosed	Alpine Rewards, LLC
Ideaya Biosciences, Inc.	90%	Options 100	not disclosed	Aon (Aon plc, Talent Solutions practice)
IGM Biosciences Inc.	not disclosed	not disclosed	not disclosed	Aon
Intellia Therapeutics Inc.	115%	Option 40 · RSU 40 · PSU 20	Yes — TSR relative to the Nasdaq Biotechnology Index	Alpine
Iteos Therapeutics Inc.	not disclosed	not disclosed	not disclosed	Radford
Kura Oncology Inc.	150%	not disclosed	No	Alpine Rewards
Kymera Therapeutics Inc.	125%	not disclosed	No	Alpine Rewards
Monte Rosa Therapeutics Inc.	not disclosed	not disclosed	not disclosed	Radford, an Aon Hewitt Company
Oric Pharmaceuticals Inc.	not disclosed	not disclosed	not disclosed	Aon
Recursion Pharmaceuticals Inc.	80%	RSU 50 · Option 50	not disclosed	Compensia
Relay Therapeutics Inc.	100%	Options 100	not disclosed	Aon
Replimune Group Inc.	not disclosed	not disclosed	No	Pearl Meyer
Sutro Biopharma Inc.	115%	Options 59 · RSU 41	not disclosed	FW Cook
Tango Therapeutics Inc.	not disclosed	not disclosed	not disclosed	Pearl Meyer
Zentalis Pharmaceuticals Inc.	105%	not disclosed	not disclosed	Anderson Pay Advisors LLC / Pay Governance LLC

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-05-15	72,458,920	6,895,394	573,204	91.31%	Passed
2025	2025-05-19	49,788,975	11,341,365	92,540	81.45%	Passed
2024	2024-05-20	30,364,001	4,022,082	77,428	88.3%	Passed
2023	2023-05-04	19,907,448	12,499,830	1,644,715	61.43%	Passed
2022	2022-05-05	34,032,385	1,380,760	6,878	96.1%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-05-15	91.31%^a
2025	2025-05-19	81.45%^b
2024	2024-05-20	88.3%^c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Broker Non-Votes Abstentions occur when shares present at the Annual Meeting are marked "Abstain." Under Delaware law, abstentions are counted as present and entitled to vote for purposes of determining whether a quorum is present but are voted neither "for" or "against" a matter, and therefore, at the Annual Meeting, abstentions will have no effect on Proposals 1, 2 or 3.”.

c. Approved under the standard stated in the filing — “Broker Non-Votes Abstentions occur when shares present at the Annual Meeting are marked "Abstain." Under Delaware law, abstentions are counted as present and entitled to vote for purposes of determining whether a quorum is present but are voted neither "for" or "against" a matter, and therefore, at the Annual Meeting, abstentions will have no effect on Proposals 1, 2 or 3.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	23 : 1
CEO total compensation	$6,374,138
Median employee compensation	$274,252

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Christine Ring	Chief Legal Officer	2026-04-02	D	8,148	$15	$124,149	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	2,000	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	A	3,750	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	2,000	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	A	2,000	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	3,214	17	53,498	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	A	2,858	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	2,000	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	3,214	17	53,498	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	A	2,000	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	2,388	17	39,749	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	A	2,000	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-05-01	D	5,394	17	90,407	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-05-04	D	8,148	17	138,210	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-05-05	D	582	17	9,996	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-05-05	D	13,473	17	223,323	Common, open-market sale	Form 4 ↗
Judith A. Reinsdorf	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Julia P. Gregory	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Roy D. Baynes	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
David L. Lacey	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Paul M. Silva	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Roger Dansey	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Anil Kapur	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Edward C. Saltzman	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-02	D	8,148	17	135,253	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-02	D	3,422	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-02	A	3,422	2	6,365	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	A	13,333	7	96,798	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	A	15,602	9	136,049	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	D	15,602	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	D	13,333	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	D	28,935	20	580,506	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-06-25	D	5,394	20	107,880	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	D	11,008	24	259,366	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	D	5,787	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	D	5,221	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	A	5,221	2	9,711	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	A	5,787	9	50,463	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	A	3,750	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	3,572	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	A	3,572	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	A	3,750	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	3,572	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	2,845	23	66,524	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	A	2,858	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	3,572	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	3,847	23	89,954	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	A	3,572	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	3,847	23	89,954	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	A	3,572	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-08-03	D	5,787	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-08-03	D	16,589	23	382,358	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-08-03	A	5,787	9	50,463	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-08-04	D	2,967	25	73,129	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-08-04	D	1,794	24	42,861	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-04	D	1,500	24	35,803	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-04	D	2,611	25	64,339	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-05	D	4,356	25	108,900	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-05	A	4,356	2	8,102	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-05	D	4,356	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-09-01	D	1,452	25	36,982	Common	Form 4 ↗
Dividend-equivalent accruals		2026-09-01	—	1,452	—	—	1 insider, 1 accrual row
Gwenn Hansen	Chief Scientific Officer	2026-09-01	A	1,452	2	2,701	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	D	5,787	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	D	5,387	26	138,417	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	A	5,787	9	50,463	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	D	400	27	10,655	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-02	D	5,786	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-02	D	5,786	23	134,149	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-02	A	5,786	9	50,454	Common	Form 4 ↗
Julia P. Gregory	Director	2026-10-14	D	22,583	0	0	Derivative, Class A Common	Form 4 ↗
Julia P. Gregory	Director	2026-10-14	D	22,583	23	528,528	Common, open-market sale	Form 4 ↗
Julia P. Gregory	Director	2026-10-14	A	22,583	2	42,004	Common	Form 4 ↗
Dividend-equivalent accruals		2026-10-15	—	1,452	—	—	1 insider, 1 accrual row
Gwenn Hansen	Chief Scientific Officer	2026-10-15	D	1,452	25	36,300	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-15	A	1,452	2	2,701	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	3,573	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	2,859	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	2,834	26	74,475	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	A	3,573	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	A	2,859	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	A	3,750	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	3,573	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	2,859	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	3,957	26	103,986	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	A	3,573	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	A	2,859	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	3,573	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	2,859	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	3,957	26	103,986	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	A	3,573	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	A	2,859	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	A	3,750	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	D	5,786	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	D	1,075	27	28,770	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	D	9,527	26	245,217	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	A	5,786	9	50,454	Common	Form 4 ↗
Dividend-equivalent accruals		2026-11-02	—	1,452	—	—	1 insider, 1 accrual row
Gwenn Hansen	Chief Scientific Officer	2026-11-02	D	1,452	27	38,914	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-11-02	A	1,452	2	2,701	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-03	D	6,113	26	157,917	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-11-04	D	1,469	16	23,800	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-11-04	D	3,300	15	50,762	Common, open-market sale	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 126 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Christine Ring	Chief Legal Officer	2026-04-02	D	8,148	$15	$124,149	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	2,000	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	A	3,750	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	2,000	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	A	2,000	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	D	3,214	17	53,498	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	A	2,858	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	2,000	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	3,214	17	53,498	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-04-30	A	2,000	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	2,388	17	39,749	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-04-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-04-30	A	2,000	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-05-01	D	5,394	17	90,407	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-05-04	D	8,148	17	138,210	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-05-05	D	582	17	9,996	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-05-05	D	13,473	17	223,323	Common, open-market sale	Form 4 ↗
Judith A. Reinsdorf	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Julia P. Gregory	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Roy D. Baynes	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
David L. Lacey	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Paul M. Silva	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Roger Dansey	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Anil Kapur	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Edward C. Saltzman	Director	2026-05-15	A	31,250	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-02	D	8,148	17	135,253	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-02	D	3,422	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-02	A	3,422	2	6,365	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	A	13,333	7	96,798	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	A	15,602	9	136,049	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	D	15,602	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	D	13,333	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-06-25	D	28,935	20	580,506	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-06-25	D	5,394	20	107,880	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	D	11,008	24	259,366	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	D	5,787	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	D	5,221	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	A	5,221	2	9,711	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-02	A	5,787	9	50,463	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	A	3,750	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	3,572	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	2,858	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	A	3,572	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	A	2,858	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	A	3,750	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	3,572	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	D	2,845	23	66,524	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	A	2,858	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	3,572	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	3,847	23	89,954	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-07-30	A	3,572	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	D	3,847	23	89,954	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-07-30	A	3,572	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-07-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-08-03	D	5,787	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-08-03	D	16,589	23	382,358	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-08-03	A	5,787	9	50,463	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-08-04	D	2,967	25	73,129	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-08-04	D	1,794	24	42,861	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-04	D	1,500	24	35,803	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-04	D	2,611	25	64,339	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-05	D	4,356	25	108,900	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-05	A	4,356	2	8,102	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-08-05	D	4,356	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-09-01	D	1,452	25	36,982	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-09-01	D	1,452	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-09-01	A	1,452	2	2,701	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	D	5,787	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	D	5,387	26	138,417	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	A	5,787	9	50,463	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-09-02	D	400	27	10,655	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-02	D	5,786	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-02	D	5,786	23	134,149	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-02	A	5,786	9	50,454	Common	Form 4 ↗
Julia P. Gregory	Director	2026-10-14	D	22,583	0	0	Derivative, Class A Common	Form 4 ↗
Julia P. Gregory	Director	2026-10-14	D	22,583	23	528,528	Common, open-market sale	Form 4 ↗
Julia P. Gregory	Director	2026-10-14	A	22,583	2	42,004	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-15	D	1,452	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-15	D	1,452	25	36,300	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-15	A	1,452	2	2,701	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	3,573	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	2,859	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	D	2,834	26	74,475	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	A	3,573	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	A	2,859	0	0	Common	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-10-30	A	3,750	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	3,573	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	2,859	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	D	3,957	26	103,986	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	A	3,573	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	A	2,859	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-10-30	A	3,750	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	3,573	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	2,859	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	3,750	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	D	3,957	26	103,986	Common, open-market sale	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	A	3,573	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	A	2,859	0	0	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-10-30	A	3,750	0	0	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	D	5,786	0	0	Derivative, Class A Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	D	1,075	27	28,770	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	D	9,527	26	245,217	Common, open-market sale	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-02	A	5,786	9	50,454	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-11-02	D	1,452	0	0	Derivative, Class A Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-11-02	D	1,452	27	38,914	Common	Form 4 ↗
Gwenn Hansen	Chief Scientific Officer	2026-11-02	A	1,452	2	2,701	Common	Form 4 ↗
Christine Ring	Chief Legal Officer	2026-11-03	D	6,113	26	157,917	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-11-04	D	1,469	16	23,800	Common, open-market sale	Form 4 ↗
Hans van Houte	Chief Financial Officer	2026-11-04	D	3,300	15	50,762	Common, open-market sale	Form 4 ↗

Sources (178 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Arthur Sands. DEF 14A, filed 2026-03-27. Section “EXECUTIVE COMPENSATION TABLES” · page 35. As printed: 6,374,138. View filing ↗
Section 01, Gwenn Hansen. DEF 14A, filed 2026-03-27. Section “EXECUTIVE COMPENSATION TABLES” · page 35. As printed: 2,498,124. View filing ↗
Section 01, Hans van Houte. DEF 14A, filed 2026-03-27. Section “EXECUTIVE COMPENSATION TABLES” · page 35. As printed: 2,296,503. View filing ↗
Section 01, Christine Ring. DEF 14A, filed 2026-03-27. Section “EXECUTIVE COMPENSATION TABLES” · page 35. As printed: 2,263,337. View filing ↗
Section 03, Gwenn Hansen OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Arthur Sands OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Gwenn Hansen RSU. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Gwenn Hansen RSU. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Christine Ring RSU. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Hans van Houte RSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 03, Christine Ring OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Hans van Houte OPTION. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-03-27. Section “CEO Pay Ratio”. As printed: 23 : 1. View filing ↗
Section 08, Roy D. Baynes. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 668,786. View filing ↗
Section 08, Roger Dansey. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 421,684. View filing ↗
Section 08, Julia P. Gregory. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 258,968. View filing ↗
Section 08, Paul M. Silva. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 230,322. View filing ↗
Section 08, Judith A. Reinsdorf. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 229,072. View filing ↗
Section 08, David L. Lacey. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 226,571. View filing ↗
Section 08, Edward C. Saltzman. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 220,218. View filing ↗
Section 08, Anil Kapur. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 217,926. View filing ↗
Section 08, Lori A. Kunkel. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 208,447. View filing ↗
Section 02, Christine Ring 2026-04-02. Form 4, filed 2026-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-04-30. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-05-01. Form 4, filed 2026-05-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-05-04. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-05-05. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-05-05. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Judith A. Reinsdorf 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Julia P. Gregory 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roy D. Baynes 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Lacey 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Paul M. Silva 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roger Dansey 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Anil Kapur 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Edward C. Saltzman 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-06-25. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-02. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-02. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-02. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-02. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-02. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-07-30. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-08-03. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-08-03. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-08-03. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-08-04. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-08-04. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-08-05. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-08-05. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-08-05. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-09-01. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-09-02. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-09-02. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-09-02. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-09-02. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-02. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-02. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-02. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Julia P. Gregory 2026-10-14. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Julia P. Gregory 2026-10-14. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Julia P. Gregory 2026-10-14. Form 4, filed 2026-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-15. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-15. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-15. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-11-02. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-11-02. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gwenn Hansen 2026-11-02. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine Ring 2026-11-03. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-11-04. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Hans van Houte 2026-11-04. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-05-15. Item 5.07 · say-on-pay result. As reported: 91.31% (votes for as printed: 72,458,920). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-05-19. Item 5.07 · say-on-pay result. As reported: 81.45% (votes for as printed: 49,788,975). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-05-21. Item 5.07 · say-on-pay result. As reported: 88.3% (votes for as printed: 30,364,001). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 538,231 + equity 0 + all other 2 = 538,233, summed across the director compensation table rows.
Arcellx Inc., Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx Inc.'s own proxy. As printed: 21,402,668. View filing ↗
Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
Ideaya Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences, Inc.'s own proxy. As printed: 9,512,640. View filing ↗
Kymera Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics Inc.'s own proxy. As printed: 8,545,609. View filing ↗
Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
Nurix Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Nurix Therapeutics, Inc.'s own proxy. As printed: 6,374,138. View filing ↗
Iteos Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Iteos Therapeutics Inc.'s own proxy. As printed: 6,085,657. View filing ↗
Replimune Group Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group Inc.'s own proxy. As printed: 5,845,982. View filing ↗
Oric Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Oric Pharmaceuticals Inc.'s own proxy. As printed: 5,567,164. View filing ↗
Celldex Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. View filing ↗
Recursion Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Recursion Pharmaceuticals Inc.'s own proxy. As printed: 5,349,065. View filing ↗
Cullinan Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cullinan Therapeutics, Inc.'s own proxy. As printed: 5,100,006. View filing ↗
Intellia Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics Inc.'s own proxy. As printed: 5,063,899. View filing ↗
Monte Rosa Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Monte Rosa Therapeutics Inc.'s own proxy. As printed: 5,032,728. View filing ↗
Kura Oncology Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology Inc.'s own proxy. As printed: 4,735,016. View filing ↗
Relay Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Relay Therapeutics Inc.'s own proxy. As printed: 4,646,454. View filing ↗
Erasca, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Erasca, Inc.'s own proxy. As printed: 4,298,838. View filing ↗
IGM Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences Inc.'s own proxy. As printed: 3,207,328. View filing ↗
C4 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics, Inc.'s own proxy. As printed: 2,940,975. View filing ↗
Tango Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Tango Therapeutics Inc.'s own proxy. As printed: 2,823,992. View filing ↗
Sutro Biopharma Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sutro Biopharma Inc.'s own proxy. As printed: 1,671,311. View filing ↗
Zentalis Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Zentalis Pharmaceuticals Inc.'s own proxy. As printed: 1,300,731. View filing ↗
Section 10a, C4 Therapeutics, Inc. reciprocity. DEF 14A. C4 Therapeutics, Inc. names Nurix Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Sutro Biopharma Inc. reciprocity. DEF 14A. Sutro Biopharma Inc. names Nurix Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗